View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
December 3, 2018

Regeneron reports positive data from Phase I REGN1979 trial

Regeneron Pharmaceuticals has reported positive results from a Phase I trial evaluating the safety, tolerability and efficacy of REGN1979 to treat patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL).

Regeneron Pharmaceuticals has reported positive results from a Phase I trial evaluating the safety, tolerability and efficacy of REGN1979 to treat patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL).

Results from the proof-of-concept trial showed an acceptable safety and tolerability profile with no observed dose-limiting toxicities (DLTs).

The trial reported no clinically-significant neurotoxicities, including no occurrence of seizures or encephalopathy among the enrolled patients.

Heavily pre-treated patients dosed with 5mg to 40mg of REGN1979 and with R/R FL grades one to 3a experienced complete overall response rate (ORR), while 90% of responders maintained a response during treatment.

REGN1979 also demonstrated promising dose-dependent clinical activity in heavily pre-treated patients with R/R DLBCL in the Phase I trial.

“It is remarkable to see a 100% response rate in heavily pre-treated relapsed or refractory follicular lymphoma patients.”

The patients treated with 5mg and 12mg of REGN1979 reported 18% ORR, while patients receiving 18mg to 40mg of REGN1979 experienced 60% increase in ORR.

Regeneron aims to continue dose-escalation in the DLBCL group and intends to begin a potentially registrational Phase II trial of REGN1979 for the treatment of R/R FL next year.

Regeneron Pharmaceuticals oncology clinical and translational sciences head Israel Lowy said: “While a high response rate is frequently observed in the first-line treatment of follicular lymphoma, it is remarkable to see a 100% response rate in heavily pre-treated relapsed or refractory follicular lymphoma patients.

“We plan to initiate a potentially registrational Phase II trial in 2019 investigating REGN1979 in relapsed or refractory follicular lymphoma, and are also considering its potential as a first-line treatment for this disease.”

REGN1979 is currently being investigated by Regeneron as a full-length bispecific monoclonal antibody designed to activate tumour killing by binding cluster of differentiation 3 (CD3) on immune system T-cells and CD20 on B-cell malignancies.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena